Sagar Lonial, MD

Articles

Dr. Lonial on the Advantage of Targeting BCMA in Multiple Myeloma

November 4th 2020

Sagar Lonial, MD, FACP, discusses the advantage of targeting BCMA in multiple myeloma.

Dr. Lonial on the Role of BCMA in Multiple Myeloma

November 2nd 2020

Sagar Lonial, MD, FACP, discusses the role of BCMA ​as a target in multiple myeloma.

Dr. Lonial on Emerging Concepts in Multiple Myeloma Treatment

June 17th 2020

Sagar Lonial, MD, FACP, discusses some of the remaining challenges to address in the multiple myeloma space.

Pivotal Studies Provide New Path in High-Risk Smoldering Myeloma

March 2nd 2020

The diagnosis and management of smoldering multiple myeloma is an area of tremendous focused research and change over the past decade, with trials yielding intriguing findings that have the potential to change practice.

Dr. Lonial on Encouraging Data With Emerging Agents in Myeloma

April 5th 2019

Sagar Lonial, MD, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses encouraging data with emerging agents in myeloma.

Dr. Lonial on Treatment of Patients With Late Relapse Myeloma

March 7th 2019

Sagar Lonial, MD, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the treatment of patients with late relapse myeloma.

Dr. Lonial on CAR T-Cell Therapy in Myeloma

August 17th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma.

Dr. Lonial on the OPTIMISMM and ELOQUENT-3 Trials in Myeloma

August 8th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the OPTIMISMM and ELOQUENT-3 trials in patients with relapsed/refractory multiple myeloma.

Dr. Lonial Discusses Emerging Agents in Relapsed/Refractory Myeloma

July 20th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses emerging agents in relapsed/refractory multiple myeloma.

Dr. Lonial Discusses Novel Agents in Multiple Myeloma

April 3rd 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses novel agents for the treatment of patients with multiple myeloma.

Dr. Lonial Discusses Ongoing Phase III Trials in Multiple Myeloma

March 21st 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses ongoing phase III studies in patients with multiple myeloma.

Dr. Lonial on Differentiating Patients With Smoldering and Multiple Myeloma

March 13th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses differentiating patients with smoldering myeloma and multiple myeloma.

Dr. Lonial Discusses Recent Updates in Multiple Myeloma

March 9th 2017

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses updates in multiple myeloma.

Dr. Lonial on Daratumumab Plus Pomalidomide in Multiple Myeloma

August 17th 2016

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the potential of the combination regimen of pomalidomide (Pomalyst) and daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Dr. Sagar Lonial on Early Treatment Versus Observation for Smoldering Multiple Myeloma

March 18th 2016

Sagar Lonial, MD, professor and chair, department of Hematology & Medical Oncology, Emory University School of Medicine, Chief Medical Officer, Winship Cancer Institute of Emory University, discusses treatment for smoldering multiple myeloma.

Dr. Lonial on Novel Mechanisms in Multiple Myeloma

December 29th 2015

Sagar Lonial, MD, chief medical officer at Winship Cancer Institute of Emory University, discusses novel mechanisms of agents used for the treatment of patients with multiple myeloma.

Novel Antibodies Poised to Transform Myeloma Treatment

July 1st 2015

The landscape of therapeutic options for patients with myeloma at all phases of treatment has rapidly changed with the development of new drugs and targets.